Earnings
Althea Group Holdings Limited is pleased to provide its Half Year Financial Report and Appendix 4D.
Two pivotal Phase 3 studies of sparsentan progressing on-track to enable potential first-in-class treatment for both FSGS and IgAN
The past year, 2018, was in many ways a decisive year for Promore Pharma
Genovis has chosen to apply IFRS 16 in advance, as well as the simplification rule regarding short-term leases.
Strong Launch Continues With More than 550 Patients on Reimbursed Commercial Crysvita® (burosumab) Therapy in the United States at End of 4th Quarter 2018, 80 Percent Increase Versus End of 3rd Quarter
Medtronic plc announced financial results for its third quarter of fiscal year 2019, which ended January 25, 2019.
Immunicum announced a collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate ilixadencel in combination with Avelumab in multi-indication phase Ib/II study ILIAD.
Karolinska Development AB publishes its Q4 and 2018 Year-End Report with a positive quarterly and full-year result. The full report is available on the Company’s website.
Israel-based Teva Pharmaceutical is the largest generic drug company in the world. One in 10 drugs taken in the U.S. are manufactured by Teva, but as generic drug prices are forced downward, the company has struggled.
Microbix Biosystems Inc. reports results for its first quarter of fiscal 2019, the three-month period ending December 31, 2018 (“Q1"), with lower sales, improving percentage gross margin, improving and positive cash flow from operations and progress toward its operational goals.
PRESS RELEASES